Study 17 of 32Orforglipron (LY-3502970) literatureThe lancet. Diabetes & endocrinologyTop journal2026
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus9
Preclinical · this one
7
Observational
1
Open-label
8
Randomised
7
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
ACardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.Lancet (London, England) · 2026 · HR 0.84; 95% CI 0.59-1.20; p<0.0001 for non-inferiority.HumanDEstablishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.Lancet (London, England) · 2026—BOral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Usersbiorxiv-preprint · 2026 · Mean weight change by 90 days was -3.1% with oral Wegovy (n=26) versus +0.4% with Foundayo (n=18), corresponding to a 3.55-percentage-point difference (95% CI, 1.02-6.08; P=0.007).HumanD<span data-teams="true">Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programsbiorxiv-preprint · 2026 · Pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%)reviewAOrforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.The Annals of pharmacotherapy · 2026 · mean 7.1% to 10.6% placebo-adjusted weight reduction with orforglipronreviewBGLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.Biomolecules & biomedicine · 2026 · Hazard ratios for NAION ranged from 1.29 to 7.64.review